Developer docs
API playgroundTry for free, no card

Search company profiles

VECT-HORUS

Full company profile

uuid0000usj

Namestring
VECT-HORUS
Legal namestring
VECT-HORUS S.A.S.
Websiteurl
vect-horus.com
Company typeenum
Private
Founded yearint
2005
Descriptiontext

VECT-HORUS S.A.S. is a French privately-held biotechnology company founded in 2005 as a spin-off of CNRS and Aix-Marseille University's Institute for NeuroPhysiopathology. The company develops and commercializes its proprietary VECTrans® technology platform, which consists of peptide-based vectors and single-domain antibodies (VHHs) that exploit receptor-mediated transcytosis (RMT) to deliver therapeutic and imaging agents across biological barriers, with a primary focus on the blood-brain barrier (BBB). Core technology components target endogenous cell-surface receptors including the LDL receptor (LDLR) and transferrin receptor 1 (TfR1), with vectors available in peptide formats under 1kDa and sdAb formats under 15kDa, conjugateable to small molecules, siRNAs, ASOs, mRNAs, proteins, antibodies, and lipid nanoparticles.

Vect-Horus operates a mixed B2B business model combining internal pipeline development with technology licensing to pharmaceutical and biotech partners. Revenue is generated through upfront payments, development and regulatory milestones, tiered royalties on licensed product sales, research collaboration fees, and cost-sharing arrangements on co-development programs. The company's partnership portfolio includes global exclusive licensing agreements with Novo Nordisk (October 2023, up to $327 million in milestones across 3 programs) and Ionis Pharmaceuticals (January 2024, double-digit million upfront plus milestones), plus co-development with RadioMedix on LDLR-targeted theranostic agents (68Ga-RMX-VH, 212Pb-RMX-VH-PKM, 203Pb-RMX-VH-PIB) for glioblastoma multiforme and pancreatic ductal adenocarcinoma, with the lead asset currently in early Phase 1 clinical trials following FDA exploratory IND clearance in 2021.

The company is headquartered in Marseille, France, on the La Timone medical campus, employs 38 people (approximately 30 in R&D), and has raised over €22 million in equity funding since inception supplemented by €8 million+ in public research grants and the REACT-EU recovery grant. Intellectual property is jointly owned with CNRS and Aix-Marseille University under long-standing academic-industry collaboration structures (Laboratoire Commun de Recherche), spanning 6+ patent families covering vector chemistry, receptor targeting, and specific vectorized therapeutic candidates.

Short descriptiontext

VECT-HORUS is a French biotechnology company developing the VECTrans® peptide and single-domain antibody platform for targeted delivery of therapeutics and imaging agents across the blood-brain barrier, licensing the technology to pharmaceutical partners such as Novo Nordisk and Ionis while co-developing LDLR-targeted theranostic agents with RadioMedix for glioblastoma and pancreatic cancer.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersMarseille, France
HQ citystring
Marseille
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
blood-brain barrier delivery, CNS drug delivery, peptide-based vectors, theranostic radiopharmaceuticals, receptor-mediated transcytosis
Industry4 codes
PRIMARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
  • Scientific Research and Development Services5417
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Commercial Physical & Biological Research8731
Product category
Biotechnology Drug Delivery
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Licensing and milestone payments
TypeLicensing Royalties
Description

Upfront payments, development, regulatory and commercial milestone payments, and tiered royalties on product sales from technology licensing agreements. Example: Novo Nordisk agreement includes upfront payment plus up to $327 million in milestones across 3 programs plus tiered royalties.

vect-horus.com
2Research collaboration fees
TypeProfessional Services
Description

Research fees from collaboration agreements for feasibility studies and co-development programs. Partners receive technology access for specific applications while Vect-Horus conducts R&D activities.

vect-horus.com
3Co-development cost sharing
TypeLicensing Royalties
Description

Cost-sharing arrangements with co-development partners (e.g., RadioMedix) where both parties share development costs until specified clinical phases, with one party leading commercialization.

globenewswire.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1VECTrans®
Description

Proprietary technology platform for targeted drug delivery across biological barriers including the blood-brain barrier

vect-horus.com
Core offering1 text field

VECT-HORUS develops proprietary molecular vectors (peptides and single-domain antibodies) that enable targeted delivery of therapeutic and imaging agents across biological barriers, particularly the blood-brain barrier, via receptor-mediated transcytosis (VECTrans® platform). The company operates a hybrid business model: internally co-developing a pipeline of theranostic radiopharmaceuticals (RMX-VH series) with partners such as RadioMedix while licensing the VECTrans® platform to global pharmaceutical partners (Novo Nordisk, Ionis, Astellas, Janssen) for CNS and RNA-targeted therapeutics development.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Vector-payload conjugates show LDLR-mediated uptake in cancer cells including GBM and PDAC with significant tumor accumulation in xenograft models
+2 more records
Product overview1 text field

VECT-HORUS operates a mixed business model combining its proprietary VECTrans® technology platform with an internal pipeline of products. The VECTrans® platform provides molecular vectors (peptides and single-domain antibodies) that enable targeted delivery of therapeutic and imaging agents across biological barriers, particularly the blood-brain barrier. The company co-develops theragnostic agents with partners like RadioMedix, including RMX-VH-GBM for glioblastoma and pancreatic cancer. VECT-HORUS licenses its technology to pharmaceutical partners (Novo Nordisk, Ionis Pharmaceuticals, OliX) for CNS and RNA-targeted therapeutics development.

Product and service6 records
1VECTrans® Technology Platform
CategoryDrug Delivery Technology Platform
Description

A proprietary drug delivery platform that uses molecular vectors (peptides targeting LDLR/TfR1 and single-domain antibodies) to ferry therapeutic and imaging payloads across biological barriers, especially the blood-brain barrier. Licensed to pharmaceutical and biotech partners for CNS, oncology, and nucleic-acid-based therapeutic programs.

268Ga-RMX-VH
CategoryRadiopharmaceutical Diagnostic Agent
Description

A Gallium-68 radiolabeled diagnostic agent for PET imaging of glioblastoma multiforme, targeting the Low Density Lipoprotein Receptor (LDLR). Co-developed with RadioMedix and advanced into exploratory IND clinical studies.

3212Pb-RMX-VH-PKM
CategoryRadiopharmaceutical Therapeutic Agent
Description

A second-generation LDLR-targeting radioconjugate for pancreatic ductal adenocarcinoma using lead-212 targeted alpha therapy, co-developed with RadioMedix.

4RMX-VH-GBM
CategoryRadiopharmaceutical Theranostic Agent
Description

A theranostic agent targeting the Low-Density Lipoprotein Receptor (LDLR) for the diagnosis and radiotherapy of glioblastoma multiforme and pancreatic ductal adenocarcinoma, co-developed with RadioMedix and currently in early Phase 1 clinical trials.

5203Pb-RMX-VH-PIB
CategoryRadiopharmaceutical Diagnostic Agent
Description

A Lead-203 labeled diagnostic agent for PET imaging of glioblastoma multiforme (GBM) and pancreatic ductal adenocarcinoma (PDAC), targeting LDLR. Co-developed with RadioMedix and advanced into exploratory IND studies.

6VH-N439
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
Strategic tierSecondaryTypeStrategic or Co-development PartnerAnnounced on2026-02-01
Description

Material Transfer and Evaluation Agreement focused on siRNA delivery for CNS disorders. Collaboration leverages Vect-Horus BBB technology with OliX RNAi therapeutics expertise.

Strategic tierSecondaryTypeStrategic or Co-development PartnerAnnounced on2025-07-01
Description

Strategic research collaboration to develop RNA-targeted therapeutics capable of crossing the blood-brain barrier for CNS diseases.

Strategic tierSecondaryTypeStrategic or Co-development PartnerAnnounced on2020-11-01
Description

Collaboration to support preclinical development of theragnostic agents. CERIMED provides medical imaging services (PET, SPECT) and preclinical/clinical imaging platform.

Strategic tierSecondaryTypeStrategic or Co-development PartnerAnnounced on2019-06-01
Description

Research Collaboration and Option Agreement using VECTrans technology to transport Astellas antibodies to the brain for CNS disease treatment.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-03-01
Description

Co-development and licensing agreement for theranostic agent targeting LDLR for diagnostic and radiotherapy of glioblastoma multiforme and pancreatic ductal adenocarcinoma. Both parties share costs until Phase 1. RadioMedix leads clinical development and future commercialization.

Strategic tierSecondaryTypeStrategic or Co-development PartnerAnnounced on2018-11-01
Description

Research collaboration to transport Janssen monoclonal antibodies to the brain for neurodegenerative disease treatment using VECTrans technology. Janssen leads further preclinical and clinical development.

Strategic tierSecondaryTypeStrategic or Co-development PartnerAnnounced on2015-06-01
Description

Scientific collaboration to develop new molecules in the field of CNS diseases using Vect-Horus receptor targeting technology.

Strategic tierSecondaryTypeStrategic or Co-development PartnerAnnounced on2015-01-01
Description

Scientific collaboration in the field of neurodegenerative diseases. Sanofi receives access to VECTrans technology for targeted brain delivery of therapeutic antibodies.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2013-11-01
Description

Scientific collaboration to develop new molecules for brain disease treatment using AAA's molecular nuclear medicine expertise combined with Vect-Horus targeting technology.

10CNRS
Strategic tierCoreTypeOthers
Description

Academic partner and co-owner of patent families. Vect-Horus is spin-off of CNRS/Aix-Marseille University. Long-term collaboration through Institut for NeuroPhysiopathology (INP).

vect-horus.com
Strategic tierCoreTypeOthers
Description

Academic founding partner. Vect-Horus established as spin-off from NICN UMR7259, now INP UMR7051. Joint patent ownership and Laboratoires Commun de Recherche (LCR) arrangement.

Strategic tierCoreTypeOthers
Description

Academic partner for research collaborations. Contributed to VECtoBrain and VEC2Brain projects alongside CNRS and CEA.

13CEA
Strategic tierCoreTypeOthers
Description

Academic research partner. Contributed to VEC2Brain project involving CEA SIMOPRO laboratory along with CNRS and INSERM.

vect-horus.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Denali Therapeutics is a clinical-stage biopharma developing engineered protein-based therapeutics designed to cross the blood-brain barrier using TfR receptor-mediated transport (their OTV platform). Highly comparable to VECT-HORUS's VECTrans platform targeting the same receptors (TfR1, LDLR) for CNS delivery of biologics.

TypeDirect peer
Description

AngioChem develops peptide-based vectors (Angiopep) that cross the BBB via LRP-1 receptor-mediated transcytosis, very similar mechanism to VECT-HORUS's VECTrans. Direct competitor in the BBB-crossing peptide vector space with partnerships across pharma for CNS drug delivery.

3ArmaGen (now Ensoma)
TypeDirect peer
Description

ArmaGen (legacy entity) developed a BBB-penetrating IgG fusion protein platform using transferrin receptor-targeting antibodies to deliver enzymes and other biologics to the brain. Direct competitor in BBB delivery platform space with overlapping mechanism (TfR) and therapeutic area focus.

TypeDirect peer
Description

CarThera is a French neurotech company developing SonoCloud, an implantable ultrasound device to transiently open the blood-brain barrier for enhanced drug delivery to the brain. Complementary approach to VECT-HORUS for solving the BBB delivery problem in CNS therapeutics, with similar French biotech profile.

TypeBroad incumbent
Description

Ionis is the leading antisense oligonucleotide (ASO) therapeutics company and is an existing VECT-HORUS licensing partner. While not a direct peer (Ionis is a much larger incumbent RNA therapeutics developer), the relationship illustrates the comparable business model of using delivery innovations to expand CNS indications.

TypeBroad incumbent
Description

Alnylam is the global leader in siRNA therapeutics with multiple approved products. Their work on extra-hepatic siRNA delivery (including CNS via TfR conjugates in their GalNAc and other conjugates) overlaps with VECT-HORUS's siRNA delivery mission. Larger incumbent in the same therapeutic modality (RNA) with overlapping delivery challenges.

TypeEmerging player
Description

Swedish biotech developing antibody-based therapeutics for neurodegenerative diseases (Alzheimer's, Parkinson's) with focus on brain-penetrating antibodies. Comparable in CNS delivery focus and Swedish/European biotech profile, though uses different delivery approach (passive/lecanemab-style) than VECT-HORUS's active receptor-mediated transport.

TypeEmerging player
Description

Wave Life Sciences is a clinical-stage genetic medicines company developing RNA base-editing and siRNA therapeutics with CNS programs (Huntington's, ALS). Comparable in CNS RNA-targeted therapeutic focus and need for efficient CNS delivery, overlapping with VECT-HORUS's core capability area.

TypeEmerging player
Description

Voyager Therapeutics develops AAV-based gene therapies for CNS diseases with a focus on engineered capsids for improved brain delivery. Comparable CNS delivery platform approach (genetic payload delivery to brain) though different modality (viral vs. peptide/antibody vectors).

TypeBroad incumbent
Description

Eli Lilly is a major incumbent in CNS therapeutics with large Alzheimer's (Kisunla/donanemab), migraine, and pain franchises. They have publicly pursued BBB-crossing technologies and represent a potential partner/acquirer tier for VECT-HORUS's BBB delivery platform.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

VECT-HORUS

Biotechnology Drug Deliveryvect-horus.com

VECT-HORUS is a French biotechnology company developing the VECTrans® peptide and single-domain antibody platform for targeted delivery of therapeutics and imaging agents across the blood-brain barrier, licensing the technology to pharmaceutical partners such as Novo Nordisk and Ionis while co-developing LDLR-targeted theranostic agents with RadioMedix for glioblastoma and pancreatic cancer.

What VECT-HORUS does

VECT-HORUS S.A.S. is a French privately-held biotechnology company founded in 2005 as a spin-off of CNRS and Aix-Marseille University's Institute for NeuroPhysiopathology. The company develops and commercializes its proprietary VECTrans® technology platform, which consists of peptide-based vectors and single-domain antibodies (VHHs) that exploit receptor-mediated transcytosis (RMT) to deliver therapeutic and imaging agents across biological barriers, with a primary focus on the blood-brain barrier (BBB). Core technology components target endogenous cell-surface receptors including the LDL receptor (LDLR) and transferrin receptor 1 (TfR1), with vectors available in peptide formats under 1kDa and sdAb formats under 15kDa, conjugateable to small molecules, siRNAs, ASOs, mRNAs, proteins, antibodies, and lipid nanoparticles.

Vect-Horus operates a mixed B2B business model combining internal pipeline development with technology licensing to pharmaceutical and biotech partners. Revenue is generated through upfront payments, development and regulatory milestones, tiered royalties on licensed product sales, research collaboration fees, and cost-sharing arrangements on co-development programs. The company's partnership portfolio includes global exclusive licensing agreements with Novo Nordisk (October 2023, up to $327 million in milestones across 3 programs) and Ionis Pharmaceuticals (January 2024, double-digit million upfront plus milestones), plus co-development with RadioMedix on LDLR-targeted theranostic agents (68Ga-RMX-VH, 212Pb-RMX-VH-PKM, 203Pb-RMX-VH-PIB) for glioblastoma multiforme and pancreatic ductal adenocarcinoma, with the lead asset currently in early Phase 1 clinical trials following FDA exploratory IND clearance in 2021.

The company is headquartered in Marseille, France, on the La Timone medical campus, employs 38 people (approximately 30 in R&D), and has raised over €22 million in equity funding since inception supplemented by €8 million+ in public research grants and the REACT-EU recovery grant. Intellectual property is jointly owned with CNRS and Aix-Marseille University under long-standing academic-industry collaboration structures (Laboratoire Commun de Recherche), spanning 6+ patent families covering vector chemistry, receptor targeting, and specific vectorized therapeutic candidates.

VECT-HORUS firmographics

Firmographics
Name
VECT-HORUS
Legal name
VECT-HORUS S.A.S.
Website
https://vect-horus.com
Company type
Private
Founded year
2005
Operating status
Operating
Headcount range
51–100 employees
Short description
VECT-HORUS is a French biotechnology company developing the VECTrans® peptide and single-domain antibody platform for targeted delivery of therapeutics and imaging agents across the blood-brain barrier, licensing the technology to pharmaceutical partners such as Novo Nordisk and Ionis while co-developing LDLR-targeted theranostic agents with RadioMedix for glioblastoma and pancreatic cancer.
Ownership category
akta.pro rank

VECT-HORUS industry classification

Industry
Product category
Biotechnology Drug Delivery
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)
SIC
Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Blood-brain barrier delivery
  • CNS drug delivery
  • Peptide-based vectors
  • Theranostic radiopharmaceuticals
  • Receptor-mediated transcytosis

Where VECT-HORUS is headquartered

Location

Headquarters

HQ city
Marseille
HQ country
France
HQ region
Europe

Offices2 records

Markets served

VECT-HORUS business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Licensing and milestone payments: Upfront payments, development, regulatory and commercial milestone payments, and tiered royalties on product sales from technology licensing agreements. Example: Novo Nordisk agreement includes upfront payment plus up to $327 million in milestones across 3 programs plus tiered royalties.
  2. Research collaboration fees: Research fees from collaboration agreements for feasibility studies and co-development programs. Partners receive technology access for specific applications while Vect-Horus conducts R&D activities.
  3. Co-development cost sharing: Cost-sharing arrangements with co-development partners (e.g., RadioMedix) where both parties share development costs until specified clinical phases, with one party leading commercialization.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

VECT-HORUS product offering

Product offering

Core offering

VECT-HORUS develops proprietary molecular vectors (peptides and single-domain antibodies) that enable targeted delivery of therapeutic and imaging agents across biological barriers, particularly the blood-brain barrier, via receptor-mediated transcytosis (VECTrans® platform). The company operates a hybrid business model: internally co-developing a pipeline of theranostic radiopharmaceuticals (RMX-VH series) with partners such as RadioMedix while licensing the VECTrans® platform to global pharmaceutical partners (Novo Nordisk, Ionis, Astellas, Janssen) for CNS and RNA-targeted therapeutics development.

Product overview

VECT-HORUS operates a mixed business model combining its proprietary VECTrans® technology platform with an internal pipeline of products. The VECTrans® platform provides molecular vectors (peptides and single-domain antibodies) that enable targeted delivery of therapeutic and imaging agents across biological barriers, particularly the blood-brain barrier. The company co-develops theragnostic agents with partners like RadioMedix, including RMX-VH-GBM for glioblastoma and pancreatic cancer. VECT-HORUS licenses its technology to pharmaceutical partners (Novo Nordisk, Ionis Pharmaceuticals, OliX) for CNS and RNA-targeted therapeutics development.

Differentiator

Problem solved

Functional benefit

Brands

  • VECTrans®: Proprietary technology platform for targeted drug delivery across biological barriers including the blood-brain barrier

Products and services

  • VECTrans® Technology Platform A proprietary drug delivery platform that uses molecular vectors (peptides targeting LDLR/TfR1 and single-domain antibodies) to ferry therapeutic and imaging payloads across biological barriers, especially the blood-brain barrier. Licensed to pharmaceutical and biotech partners for CNS, oncology, and nucleic-acid-based therapeutic programs.
  • 68Ga-RMX-VH A Gallium-68 radiolabeled diagnostic agent for PET imaging of glioblastoma multiforme, targeting the Low Density Lipoprotein Receptor (LDLR). Co-developed with RadioMedix and advanced into exploratory IND clinical studies.
  • 212Pb-RMX-VH-PKM A second-generation LDLR-targeting radioconjugate for pancreatic ductal adenocarcinoma using lead-212 targeted alpha therapy, co-developed with RadioMedix.
  • RMX-VH-GBM A theranostic agent targeting the Low-Density Lipoprotein Receptor (LDLR) for the diagnosis and radiotherapy of glioblastoma multiforme and pancreatic ductal adenocarcinoma, co-developed with RadioMedix and currently in early Phase 1 clinical trials.
  • 203Pb-RMX-VH-PIB A Lead-203 labeled diagnostic agent for PET imaging of glioblastoma multiforme (GBM) and pancreatic ductal adenocarcinoma (PDAC), targeting LDLR. Co-developed with RadioMedix and advanced into exploratory IND studies.
  • VH-N439

Quantifiable outcome

  • Vector-payload conjugates show LDLR-mediated uptake in cancer cells including GBM and PDAC with significant tumor accumulation in xenograft models
  • +2 more outcomes

Companies that use VECT-HORUS

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles3 records

VECT-HORUS technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

VECT-HORUS partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered secondary, core and minor.

  • OliX PharmaceuticalssecondaryStrategic or Co-development Partner · 1 February 2026Material Transfer and Evaluation Agreement focused on siRNA delivery for CNS disorders. Collaboration leverages Vect-Horus BBB technology with OliX RNAi therapeutics expertise.
  • Secarna PharmaceuticalssecondaryStrategic or Co-development Partner · 1 July 2025Strategic research collaboration to develop RNA-targeted therapeutics capable of crossing the blood-brain barrier for CNS diseases.
  • CERIMEDsecondaryStrategic or Co-development Partner · 1 November 2020Collaboration to support preclinical development of theragnostic agents. CERIMED provides medical imaging services (PET, SPECT) and preclinical/clinical imaging platform.
  • Astellas PharmasecondaryStrategic or Co-development Partner · 1 June 2019Research Collaboration and Option Agreement using VECTrans technology to transport Astellas antibodies to the brain for CNS disease treatment.
  • RadioMedixcoreStrategic or Co-development Partner · 1 March 2019Co-development and licensing agreement for theranostic agent targeting LDLR for diagnostic and radiotherapy of glioblastoma multiforme and pancreatic ductal adenocarcinoma. Both parties share costs until Phase 1. RadioMedix leads clinical development and future commercialization.
  • Janssen Pharmaceuticals (Johnson & Johnson)secondaryStrategic or Co-development Partner · 1 November 2018Research collaboration to transport Janssen monoclonal antibodies to the brain for neurodegenerative disease treatment using VECTrans technology. Janssen leads further preclinical and clinical development.
  • ServiersecondaryStrategic or Co-development Partner · 1 June 2015Scientific collaboration to develop new molecules in the field of CNS diseases using Vect-Horus receptor targeting technology.
  • SanofisecondaryStrategic or Co-development Partner · 1 January 2015Scientific collaboration in the field of neurodegenerative diseases. Sanofi receives access to VECTrans technology for targeted brain delivery of therapeutic antibodies.
  • Advanced Accelerator Applications (AAA)minorStrategic or Co-development Partner · 1 November 2013Scientific collaboration to develop new molecules for brain disease treatment using AAA's molecular nuclear medicine expertise combined with Vect-Horus targeting technology.
  • CNRScoreOthersAcademic partner and co-owner of patent families. Vect-Horus is spin-off of CNRS/Aix-Marseille University. Long-term collaboration through Institut for NeuroPhysiopathology (INP).
  • Aix-Marseille UniversitycoreOthersAcademic founding partner. Vect-Horus established as spin-off from NICN UMR7259, now INP UMR7051. Joint patent ownership and Laboratoires Commun de Recherche (LCR) arrangement.
  • INSERMcoreOthersAcademic partner for research collaborations. Contributed to VECtoBrain and VEC2Brain projects alongside CNRS and CEA.
  • CEAcoreOthersAcademic research partner. Contributed to VEC2Brain project involving CEA SIMOPRO laboratory along with CNRS and INSERM.

Scale indicators7 records

Recent moves8 records

Expansion highlights5 records

VECT-HORUS competitors and assessment

Company assessment

Direct peers

  • Denali Therapeutics: Denali Therapeutics is a clinical-stage biopharma developing engineered protein-based therapeutics designed to cross the blood-brain barrier using TfR receptor-mediated transport (their OTV platform). Highly comparable to VECT-HORUS's VECTrans platform targeting the same receptors (TfR1, LDLR) for CNS delivery of biologics.
  • AngioChem: AngioChem develops peptide-based vectors (Angiopep) that cross the BBB via LRP-1 receptor-mediated transcytosis, very similar mechanism to VECT-HORUS's VECTrans. Direct competitor in the BBB-crossing peptide vector space with partnerships across pharma for CNS drug delivery.
  • ArmaGen (now Ensoma): ArmaGen (legacy entity) developed a BBB-penetrating IgG fusion protein platform using transferrin receptor-targeting antibodies to deliver enzymes and other biologics to the brain. Direct competitor in BBB delivery platform space with overlapping mechanism (TfR) and therapeutic area focus.
  • CarThera: CarThera is a French neurotech company developing SonoCloud, an implantable ultrasound device to transiently open the blood-brain barrier for enhanced drug delivery to the brain. Complementary approach to VECT-HORUS for solving the BBB delivery problem in CNS therapeutics, with similar French biotech profile.

Broad incumbents

  • Ionis Pharmaceuticals: Ionis is the leading antisense oligonucleotide (ASO) therapeutics company and is an existing VECT-HORUS licensing partner. While not a direct peer (Ionis is a much larger incumbent RNA therapeutics developer), the relationship illustrates the comparable business model of using delivery innovations to expand CNS indications.
  • Alnylam Pharmaceuticals: Alnylam is the global leader in siRNA therapeutics with multiple approved products. Their work on extra-hepatic siRNA delivery (including CNS via TfR conjugates in their GalNAc and other conjugates) overlaps with VECT-HORUS's siRNA delivery mission. Larger incumbent in the same therapeutic modality (RNA) with overlapping delivery challenges.
  • Eli Lilly (Lilly Neuroscience): Eli Lilly is a major incumbent in CNS therapeutics with large Alzheimer's (Kisunla/donanemab), migraine, and pain franchises. They have publicly pursued BBB-crossing technologies and represent a potential partner/acquirer tier for VECT-HORUS's BBB delivery platform.

Emerging players

  • BioArctic: Swedish biotech developing antibody-based therapeutics for neurodegenerative diseases (Alzheimer's, Parkinson's) with focus on brain-penetrating antibodies. Comparable in CNS delivery focus and Swedish/European biotech profile, though uses different delivery approach (passive/lecanemab-style) than VECT-HORUS's active receptor-mediated transport.
  • Wave Life Sciences: Wave Life Sciences is a clinical-stage genetic medicines company developing RNA base-editing and siRNA therapeutics with CNS programs (Huntington's, ALS). Comparable in CNS RNA-targeted therapeutic focus and need for efficient CNS delivery, overlapping with VECT-HORUS's core capability area.
  • Voyager Therapeutics: Voyager Therapeutics develops AAV-based gene therapies for CNS diseases with a focus on engineered capsids for improved brain delivery. Comparable CNS delivery platform approach (genetic payload delivery to brain) though different modality (viral vs. peptide/antibody vectors).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

VECT-HORUS social profiles

Digital presence

VECT-HORUS financial estimates

Financial estimate

Revenue estimate

Valuation estimate

VECT-HORUS leadership team

Management profile

Number of profiles

Profiles6 records

VECT-HORUS funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

VECT-HORUS M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about VECT-HORUS

What does VECT-HORUS do?

VECT-HORUS develops proprietary molecular vectors (peptides and single-domain antibodies) that enable targeted delivery of therapeutic and imaging agents across biological barriers, particularly the blood-brain barrier, via receptor-mediated transcytosis (VECTrans® platform). The company operates a hybrid business model: internally co-developing a pipeline of theranostic radiopharmaceuticals (RMX-VH series) with partners such as RadioMedix while licensing the VECTrans® platform to global pharmaceutical partners (Novo Nordisk, Ionis, Astellas, Janssen) for CNS and RNA-targeted therapeutics development.

Is VECT-HORUS a public or private company?

VECT-HORUS is a private company. It is classified as venture growth investor backed and is currently operating.

When was VECT-HORUS founded?

VECT-HORUS was founded in 2005. It employs 51 to 100 people.

Where is VECT-HORUS based?

VECT-HORUS is headquartered in Marseille, France, in the Europe region.

How does VECT-HORUS make money?

Three revenue lines are on record. Licensing and milestone payments are the primary driver. The others are research collaboration fees and co-development cost sharing.

Who are VECT-HORUS's main competitors?

Direct peers on record are Denali Therapeutics, AngioChem, ArmaGen (now Ensoma) and CarThera. Broad incumbents are Ionis Pharmaceuticals, Alnylam Pharmaceuticals and Eli Lilly (Lilly Neuroscience). Emerging players are BioArctic, Wave Life Sciences and Voyager Therapeutics.

Does VECT-HORUS have an API?

No public API is recorded for VECT-HORUS.

What industry is VECT-HORUS in?

VECT-HORUS's product category is Biotechnology Drug Delivery. Its primary akta.pro industry code is HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization), with a secondary code of HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireVect-Horus conclut un accord de collaboration et d’option de licence avec Servier afin de déveloper des traitements ciblés à base d'oligonucléotides pour les maladies rares du système nerveux centralVect-Horus, a private Marseille-based biotechnology company, has signed a research collaboration and exclusive license option agreement with Servier, an independent international pharmaceutical group, to develop oligonucleotide-based targeted therapies for rare central nervous system diseases. Under the deal, Vect-Horus will leverage its proprietary VECTrans® technology platform to enable Servier's oligonucleotide treatments to cross the blood-brain barrier. Servier gains an exclusive option to advance selected programs into clinical development and commercialization, while Vect-Horus is eligible to receive research and exclusivity fees, upfront and milestone payments, and single-digit royalties on net annual sales of any commercialized products.GlobeNewswireVect-Horus announces collaboration and license option agreement with Servier to develop targeted oligonucleotide therapeutics for rare CNS diseasesVect-Horus announced a research evaluation and exclusive license option agreement with Servier to develop targeted oligonucleotide therapeutics for rare central nervous system diseases. Under the agreement, Vect-Horus will leverage its proprietary VECTrans® technology platform to enable delivery of Servier's oligonucleotides across biological barriers to the brain, with Servier gaining an exclusive option to advance selected programs into clinical development and commercialization. Vect-Horus will receive research and exclusivity fees during the option period, and upon option exercise, will be eligible for upfront payments, milestone payments, and single-digit royalties on future product sales.FinancialContent Business PageVect-Horus announces collaboration and license option agreement with Servier to develop targeted oligonucleotide therapeutics for rare CNS diseasesVect-Horus, a privately held French biotechnology company, has entered into a research evaluation and exclusive license option agreement with Servier to develop targeted oligonucleotide therapeutics for rare central nervous system diseases. Under the deal, Vect-Horus will leverage its proprietary VECTrans® platform to enable Servier's oligonucleotides to cross biological barriers and reach the brain. Servier gains an exclusive option to advance selected programs into clinical development and commercialization, with Vect-Horus eligible to receive research fees, upfront payments, milestone payments, and single-digit royalties on future product sales.ContractpharmaVect-Horus, Servier Ink CNS Drug Delivery DealVect-Horus, a privately held biotechnology company, has signed a research evaluation and exclusive license option agreement with Servier to develop targeted oligonucleotide therapeutics for central nervous system diseases. Under the deal, Vect-Horus will leverage its proprietary VECTrans technology platform to enable Servier's oligonucleotide therapies to cross biological barriers and reach the brain. Servier will have an exclusive option to advance selected compounds into clinical development and commercialization following an initial evaluation period, with Vect-Horus eligible to receive milestone payments and single-digit royalties on net product sales.BioSpaceRadioMedix to Present at SNMMI 2026 and Mark 20 Years of Radiopharmaceutical InnovationRadioMedix will present at SNMMI 2026 in Los Angeles, with CEO Ebrahim Delpassand and CIO Izabela Tworowska leading sessions on alpha therapy and lead-212 radiopharmaceuticals. The company marks its 20th anniversary, having been founded in 2006, and will share preclinical data on its second-generation LDLR-targeting radioconjugate for pancreatic cancer.GlobeNewswireVect-Horus appoints Claudia Fromond as new Director of R&DVect-Horus appointed Claudia Fromond as Director of R&D, bringing over 20 years of experience in immuno-oncology and CNS drug delivery. She previously led first-in-class programs at Advesya, OSE Immunotherapeutics, and Ablynx-Sanofi. The appointment aims to advance the company's vector-based drug delivery technology.GlobeNewswireVect-Horus Enters a CNS-Focused Research Collaboration with OliX PharmaceuticalsVect-Horus and OliX Pharmaceuticals signed an MTEA to evaluate Vectrans BBB shuttle technology for delivering OliX's siRNAs into the CNS. The collaboration will assess delivery efficiency and biodistribution, aiming to validate CNS siRNA therapeutics and support OliX's expansion into CNS pipelines.GlobeNewswireRadioMedix and Vect-Horus Announce First Patient Dosed in Exploratory Clinical Study of 203Pb-RMX-VH-PIB for Glioblastoma Multiforme and Pancreatic Ductal AdenocarcinomaRadioMedix and Vect-Horus announced the first patient dosed in an exploratory IND study of 203Pb-RMX-VH-PIB for glioblastoma and pancreatic ductal adenocarcinoma. The agent targets LDLR, overexpressed in these tumors, and will serve as a companion diagnostic for future targeted alpha therapy.NatureHow blood–brain barrier technology is unleashing CNS therapiesVect-Horus's VECTrans platform enables targeted drug delivery across the blood-brain barrier, partnering with Novo Nordisk and Ionis for CNS therapies. The company has over 10 collaborations, including exclusive licenses, and is in talks with additional pharma and biotech firms.